Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
Department of Health and Human Services ▸ National Institutes of Health
Description
What it is: An NIH cooperative agreement (U01) under the Regenerative Medicine Innovation Project (RMIP) that supports investigator-initiated research to advance regenerative medicine. Clinical trials are not allowed under this announcement.
Goal: Generate the preclinical, translational, and regulatory-enabling evidence, tools, and standards needed to move regenerative medicine products toward future clinical testing.
What it can fund:
Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
Source
Grant ID
RFA-AR-25-013
Funding Source
Department of Health and Human Services ▸ National Institutes of Health
Eligibility
The following categories of applicants are invited to apply:
- City or township governments
- County governments
- For profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities/Indian housing authorities
- Small businesses
- Special district governments
- State governments
Awards & Funding
Total Funding
$400,000
Funding Amount
Discretionary
Links
Documents
Similar opportunities
- Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
- Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional)
- Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Optional)
- Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)
- Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)